Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data

被引：0
|
作者：
Colombel, Jean-Frederic
Lemann, Marc
Allez, Matthieu
Mitchev, Krassimir
Jamoul, Corinne
Hebuterne, Xavier
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A181 / A181
页数：1
相关论文
共 50 条
  • [31] Assessment of the Efficacy of Certolizumab Pegol in the Maintenance of Response for the Treatment of Crohn's Disease
    Lee, Scott D.
    Ko, Cynthia W.
    Wahbeh, Ghassan
    Cullinan, Cory
    Etter, Scott
    Sinanan, Mika N.
    Wheat, Chelle
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S282 - S282
  • [32] Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Nikolaus, Susanna
    Schoelmerich, Juergen
    Panes, Julian
    Sandborn, William J.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (07): : 1574 - 1582
  • [33] Higher remission and maintenance of response rates with subcutaneous monthly certolizumab pegol in patients with recent-onset Crohn's disease:: Data from PRECiSE 2
    Sandborn, William J.
    Colombel, Jean-Frederic
    Panes, Julian
    Schoelmerich, Juergen
    McColm, Juliet A.
    Schreiber, Stefan
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S434 - S435
  • [34] Crohn's Disease Behavior as a Risk Factor for Loss of Maintenance of Remission in Patients Treated With Certolizumab Pegol: Results From the PRECiSE 3 Study
    Rubin, David
    Randall, Charles
    Coarse, Jason
    Kosutic, Gordana
    Spearman, Marshall
    Ambarkhane, Sumeet
    Jojic, Njegica
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S508 - S509
  • [35] Baseline Corticosteroid Use and Corticosteroid-Free Clinical Remission in Crohn's Disease Patients Treated With Certolizumab Pegol in the PRECiSE 2 Trial
    Sandborn, William
    Feagan, Brian
    Lee, Scott
    Hanauer, Stephen
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 : S23 - S24
  • [36] Fecal Calprotectin Concentration and Clinical Response to Certolizumab Pegol in Patients with Active Crohn's Disease: Results from PRECiSE 2
    Sandborn, William
    Pierre-Louis, Bosny
    Ullman, Thomas
    Binion, David
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S453 - S453
  • [37] Fecal calprotectin concentration and clinical response to certolizumab pegol in patients with active Crohn's disease: results from PRECiSE 2
    Sandborn, William J.
    Pierre-Louis, Bosny
    Ullman, Thomas A.
    Binion, David G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S24 - S25
  • [38] Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
    Sandborn, William J.
    Schreiber, Stefan
    Feagan, Brian G.
    Rutgeerts, Paul
    Younes, Ziad H.
    Bloomfield, Ralph
    Coteur, Geoffroy
    Guzman, Juan Pablo
    D'Haens, Geert R.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (08) : 670 - U84
  • [39] Use of Certolizumab Pegol in the Management of Acute Extraintestinal Manifestations of Active Crohn's Disease
    Randall, Charles
    Ford, Janet
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S354 - S354
  • [40] Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
    Vande Casteele, N.
    Feagan, B. G.
    Vermeire, S.
    Yassine, M.
    Coarse, J.
    Kosutic, G.
    Sandborn, W. J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 229 - 237
12345